Izrael - hebrajski - Ministry of Health

medison pharma ltd - ataluren - גרנולות להכנת תרחיף פומי - ataluren 1000 mg - ataluren

Izrael - hebrajski - Ministry of Health

medison pharma ltd - ataluren - גרנולות להכנת תרחיף פומי - ataluren 125 mg - ataluren

Izrael - hebrajski - Ministry of Health

medison pharma ltd - ataluren - גרנולות להכנת תרחיף פומי - ataluren 250 mg - ataluren

Izrael - hebrajski - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib

Izrael - hebrajski - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib

Izrael - hebrajski - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib

Izrael - hebrajski - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - hebrajski - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*